Nicox: Issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares awarded to existing Aciex shareholders following the US FDA's approval of ZERVIATE

Press Release

Nicox announces the issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares awarded to existing Aciex shareholders following the US FDA's approval of the new drug application in the US for ZERVIATE (cetirizine ophthalmic solution) 0.24%.

8 June 2017
Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, has announced a capital increase of a nominal amount of €597,897 by means of the issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares following the approval by the US FDA (Food and Drug Administration) of the new drug application in the US for ZERVIATE (cetirizine ophthalmic solution) 0.24% (see the Company's press release of 31 May 2017), in order to provide existing Aciex shareholders with the Nicox shares due to them in respect of their category A-1 stock warrants (see the document dated 30 September 2014 registered with the Autorité des Marchés Financiers under no. E. 14-060 available on Nicox' website). These new shares are issued at their face value and fully paid up, with the amount deducted from the acquisition premium account.

The impact of the issue on the stake held in the Company's share capital and the share of equity as at 31 December 2016 of a shareholder holding 1% of share capital at the time of the issue (calculations based on a non-diluted basis and a fully diluted basis, i.e. taking into account the issuance of a maximum of 999,120 new shares following (i) the exercise of the all stock warrants and stock options and (ii) the definitive acquisition of all free shares outstanding as at 31 December 2016).

 About Nicox

Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma. Nicox currently has an approved NDA product and another product at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com .            

Analyst coverage

Bryan, Garnier & Co   Hugo Solvet                 Paris, France
Invest Securities          Martial Descoutures    Paris, France
Gilbert Dupont             Damien Choplain        Paris, France
Stifel                             Christian Glennie        London, UK

Upcoming financial and business conferences

June 19-22                    2017 BIO International Convention                                                     San Diego, US
September 25-27          Cantor Fitzgerald's 3rd Annual Healthcare Conference                      New York; US

Contacts

Nicox
Gavin Spencer,
Executive Vice President Corporate Development
T +33 (0)4 97 24 53 00
[email protected]
Investor Relations
Europe
NewCap
Julien Perez, Valentine Brouchot
T +33 (0)1 44 71 94 94
[email protected]
Media Relations
United Kingdom
Jonathan Birt
T +44 7860 361 746
[email protected]
United States
Argot Partners
Melissa Forst
T +1 (212) 600-1902
[email protected]
France
NewCap
Nicolas Merigeau
T +33 (0)1 44 71 94 98
[email protected]

United States
Argot Partners
Eliza Schleifstein
T +1 (917) 763-8106
[email protected]

Disclaimer

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/a1550d6b-9597-43bc-be4c-e8e0add54dee